Indian Drug Authorities Halt Eye Drop Production at Sun Pharma Plant Over Safety Lapses

Federal and state regulators have banned Sun Pharmaceutical Industries from making, selling, and distributing eye-care products from its manufacturing site in Assam following a joint inspection that revealed severe flaws in its quality management system. The Central Drugs Standard Control Organisation and the Drugs Controller Assam issued the shutdown order on August 20 after the company pulled back roughly eleven eye-care brands in July. Authorities demanded further information regarding the recall of 332 batches of ophthalmic suspension items used for treating eye conditions. Regulators initially served a show-cause notice to the firm on August 10 and escalated the matter after finding the company's reply unsatisfactory.

Company Response And Recall Details

Sun Pharma stated on October 30 that it voluntarily paused its production activities and informed authorities while implementing corrective actions, though it did not comment on the recall itself. The affected items were produced at the company's unit in Kokjhar village and include brands such as Lotepred, Nepalact, and Depopred. Industry experts estimate that the withdrawn stock could span hundreds of thousands of bottles. The eye-care segment accounts for approximately three percent of the company's domestic income and remains a priority for its United States market.

Broader Scrutiny

This regulatory action follows a June patient-safety warning from the All India Ophthalmological Society regarding contaminated batches of Predmet eye drops, prompting an investigation where sealed bottles were found to be tainted. Santosh Honavar, secretary of the society, confirmed that these drops were also pulled back. This adds to past regulatory hurdles for the company, including a U.S. food and drug administration block on shipments from its Gujarat facility last year due to contamination control issues. Indian medicine standards have faced intense domestic and international oversight following instances where locally produced cough syrups were linked to children's deaths in multiple countries.

Context

Drug regulators routinely inspect pharmaceutical plants to ensure products meet safety standards before reaching patients. When critical process failures or contamination risks are identified, agencies possess the legal authority to halt manufacturing until the company proves it has fixed the underlying issues. Ophthalmology products require strict sterile conditions because any bacteria introduced directly into the eye can lead to serious infections and vision damage.